A B S T R A C T We have recently proposed that "down regulation" of the insulin receptor may be one of the many biological responses of a cell to insulin. In an attempt to further explore this hypothesis we have studied insulin action, binding, and degradation in freshly isolated hepatocytes from rats rendered insulin resistant by the administration of dexamethasone, 1.0 mg/kg every other day, for 1 and 4 wk, and in dexamethasone-treated (0.1 ,uM for 24 h) primary cultures of hepatocytes from normal rats.
Hepatocytes from animals treated with dexamethasone for 4 wk were resistant to insulin with regard to aminoisobutyrate uptake, yet both insulin binding and insulin degradation returned to the levels observed in hepatocytes from control animals.
Primary cultures of hepatocytes from normal rats exposed to dexamethasone, 0.1 ,uM, in vitro for 24 h were similar to hepatocytes from rats treated with dexamethasone for 4 wk in that they were insulin resistant with regard to aminoisobutyrate uptake and had normal to increased insulin binding. Insulin degradation was also similar. These cells were resistant to the ability of insulin, 0.1 ,uM, to down regulate its receptor whereas parallel cultures treated with insulin in the absence of dexamethasone had a 52% decrease in insulin binding.
These data indicate that hepatocytes that are insulin responsive respond to in vivo hyperinsulinemia by a decrease in the number of insulin receptors and by increased insulin degradation. Hepatocytes rendered resistant to insulin both in vivo and in vitro are resistant to these effects of insulin. These studies emphasize the importance of postbinding events in the modulation of insulin binding, action, and degradation, and support the hypothesis that down regulation of the hepatocyte insulin receptor is one of the many biological actions of insulin. They also help explain how a cell can be insulin resistant and have a normal number of insulin binding sites in the presence of hyperinsulinemia. INTRODUCTION An inverse relationship between insulin binding to target tissues and the concentration of hormone to which cells are exposed has been observed in some human metabolic states (1) (2) (3) , animal disease models (4, 5) , and in vitro cell systems (6) (7) (8) (9) (10) . Such down regulation has been implicated in the development of insulin resistance in hyperinsulinemic states. There are, however, many insulin-resistant states that are associated with elevated circulating insulin levels and normal insulin binding (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) . These exceptions indicate that the mechanism(s) of down regulation may be more complex than previously thought.
Although the specific mechanism(s) involved in down regulation of the insulin receptor by insulin are unknown, we have recently proposed that this may be one of the many biological responses of a cell to insulin (6) . Evidence for this includes the ability of agents that mimic the effects of insulin without interacting with the insulin binding site to down regulate the insulin receptor (6) , the inability of insulin to down regulate the insulin receptor of turkey erythrocytes, a cell that lacks active macromolecular synthesis (22) , and the demonstration that cellular ATP levels may regulate insulin binding (23) . The implications of these observations are that if a cell were resistant to some effects of insulin it might also be resistant to the ability of insulin to down regulate its receptor. Such an effect could be classified as an example of postbinding insulin resistance.
In an attempt to further explore this hypothesis we have studied insulin action, binding, and degradation in freshly isolated hepatocytes from rats made resistant to insulin by the administration of glucocorticoids for 1 and 4 wk. In addition, we have studied the effects of glucocorticoids on insulin binding, action, and degradation when added in vitro to primary cultures of hepatocytes from normal rats. The data demonstrate the importance of postbinding events in the modulation of insulin action, binding, and degradation in the liver and suggest that a hepatocyte must be insulin responsive for insulin to down regulate its receptor. Preparation of hepatocytes. The liver perfusion and the isolation and suspension of hepatocytes were performed as described (5) with the exception that for insulin binding and degradation the cells were suspended at 0.8-1.2 X 106 cells/ ml, and both binding and degradation were assessed at 25°C.
METHODS
Primary cultures of hepatocytes were performed as described (6) . When present, insulin (0.1 ,uM) and dexamethasone (0.1 AM) were added at the time of the first medium change 4 h after plating. Insulin was readded every 8 h. After 24 h of culture the cells were washed as described (6) in Hanks'-HEPES buffer, pH 7.4, containing glucose (8 mM) and bovine serum albumin (10 mg/ml). Insulin action is assessed in the same buffer at 37°C and insulin binding and degradation at 25°C.
Binding of 125I-labeled insulin. Insulin was iodinated with chloramine T according to the method of Cuatrecasas (24) and insulin binding assessed as described (5, 6) . Nonspecific binding is <10% in all cell groups. Maximum insulin binding is achieved at 15-30 min and is maintained for 60-90 min (25, 26) . All binding data reported were obtained at 45 min.
In some studies hepatocytes were solubilized overnight at 40C with constant stirring in Hanks'-HEPES buffer, pH 7.4, containing 10 mg/ml bovine serum albumin, 1% Triton X-100, and 1 mM N-ethylmaleimide. The solubilized cells are centrifuged at 48,000 g for 30 min and the supernatant diluted 1:10 with the above buffer without Triton X-100. Aliquots of the supernatant containing the solubilized insulin receptor are incubated at 250C for 45 min with 125I-labeled insulin, 0.1 nM, plus increasing concentrations of unlabeled insulin. The bound insulin and added bovine gamma globulin are precipitated with 12.5% polyethylene glycol at 40C (27) . 1251-labeled insulin is purified on a Bio-Gel (Bio-Rad Laboratories, Richmond, CA) P-30 column immediately before use. Nonspecific binding, which is the amount of 125I-labeled insulin (0.1 nM) bound in the presence of unlabeled insulin (1 MAM), is 27±3% of total insulin binding at tracer concentrations of '251-labeled insulin (0.1 nM). In these experiments the data is normalized by the number of cells extracted.
Insulin degradation studies. The degradation of '251-labeled insulin in the medium was determined by precipitation with trichloroacetic acid after a 45-min incubation of hepatocytes with '251-labeled insulin, 0.1 nM, plus increasing concentrations of unlabeled insulin at 25°C (25) . The leakage of degradative enzymes into the medium accounts for <1% of the total degradation observed in freshly isolated and primary cultures of hepatocytes under the conditions of these studies (25, 26) . The nature of the 1251 associated with the cells is determined by solubilization of the hepatocytes in 4 M urea, 1 M acetic acid, and 0.1% Triton X-100 followed by chromatography on Sephadex G-50 as reported (25) .
Aminoisobutyric acid (AIB)1 uptake. To measure AIB uptake freshly isolated and primary cultures of hepatocytes were incubated in Hanks'-HEPES buffer, pH 7.4, containing 8 mM glucose in the absence and presence of varying concentrations of insulin for 2 h at 37°C as reported by LeCam et al. (28) . Following this preincubation, [14C] AIB (0.1 mM, 1.4 mCi/mmol) was added. Uptake is linear for at least 20 ' Abbreviations used in this paper: AIB, aminoisobutyric acid; Dex, dexamethasone. min in both cell systems, and therefore the reaction was terminated at 10 min to obtain initial rates of uptake. For freshly isolated hepatocytes uptake was terminated by the oil separation method as reported (5) . For 
RESULTS
In vivo effects of I wk of dexamethasone treatment on insulin binding and action in freshly isolated hepatocytes. Animals receiving dexamethasone for 1 wk (group I Dex) weighed 188±11 g (n = 6), which is similar to that of the age-and weight-matched control animals (199±12 g, n = 6). The size of the isolated hepatocytes as assessed by water space was also similar and was 4.0±0.8 and 3.9±0.9 jul cell water/106 cells for group I Dex and control animals, respectively. Serum insulin levels, however, were significantly higher in the group I Dex animals (60±4 gU/ml) than in the control rats (36±10 MU/ml, P < 0.01). The elevated serum insulin levels in the presence of similar serum glucose levels (228±13 and 205±8 mg/100 ml in group I Dex and control animals, respectively) are suggestive of an insulin-resistant state induced by dexamethasone. Because the rats were fed overnight, these glucose values represent postprandial values.
A comparison of freshly isolated hepatocytes from group I Dex and control animals with respect to insulin binding and insulin action is illustrated in Fig. 1 Hepatocytes from rats receiving dexamethasone for 1 wk bound an average of 71±20% less insulin than those from control animals at insulin concentrations from 0.1 nM to 0.1 gM (Fig. 1) . This difference was significant at insulin concentrations of 0.1 nM to 5 nM (P < 0.05-P < 0.001). Because of the experimental error at higher concentrations of insulin, there is no statistically significant difference in insulin binding to hepatocytes from control and group I Dex animals at insulin concentrations of 10 nM and 0.1 1M. An analysis of the average affinity by the method of DeMeyts and Roth (29) indicates that at the lowest receptor occupancy (B/RO = 2-5%) hepatocytes from group I Dex animals have a 33% decrease in average affinity for insulin (P < 0.05). Whereas these data should be interpreted with caution because of the large experimental error in the determination of the R0 value, the decrease in average affinity is consistent with the significant increase in the concentration of native insulin necessary to compete for 50% of the tracer '25I-labeled insulin specifically bound to cells from group I Dex animals (1.5±0.4 nM, n = 3) as compared with cells from control animals (0.36+0.05 nM, n = 4, P < 0.05). Taken together, these data indicate that 1 wk of dexamethasone treatment leads to a decrease in insulin binding due to a significant decrease in affinity of the insulin receptor for insulin and possibly also a decrease in the total number of available insulin binding sites.
The apparent decrease in receptor number is supported by the data in Fig. 2 . Because there are specific intracellular binding sites for insulin (30) , we investigated whether 1 wk of dexamethasone treatment has an effect on the total number of cellular insulin binding sites. Freshly isolated hepatocytes from control and group I Dex animals were solubilized and insulin binding was analyzed as described in Methods. Fig. 2 is a Scatchard analysis of these data. The solubilized hepatocytes from group I Dex animals bind significantly less (P < 0.05 to P < 0.02) insulin than cells from control rats at every insulin concentration used. This decrease in binding appears to be mainly due to a decrease in receptor number because there is no significant difference in average affinity (data not shown) and the concentration of insulin that competes for 50% of specific '251-labeled insulin (0.1 nM) binding is the same in the two groups of cells (2.1 nM for solubilized receptors from control animals and 1.9 nM for receptors from group I Dex animals). Interestingly changes in affinity are not observed in this assay as compared with the whole cell preparation where apparent affinity decreased in cells from group I Dex animals ( Fig. 1) . Because the majority of insulin binding sites are intracellular (Figs. 1, 2) 4 wk (group II Dex) were similar to control animals both in body weight (252±24 g, n = 5 and 305±20 g, n = 4, respectively) and hepatocyte size (4.9±0.9 and 4.1±1.1 pl cell water/106 cells, respectively). In addition both groups of animals had similar serum glucose concentrations (225±8 and 246±25 mg/100 ml in control and group II Dex animals, respectively). Serum insulin levels were significantly higher, however, in the group II Dex animals (123±17 iU/ml and 77±9 ,uU/ml in group II Dex and control animals, respectively, P < 0.05), again suggesting insulin resistance in this animal model. Fig. 3 (26) and others (31) have demonstrated that in hepatocytes insulin binding may be rate limiting for insulin degradation. The decrease in binding observed in cells from group I Dex animals (71±20%) cannot, however, be explained by the small decrease (7.4 to 7.1%) in intact free '25I-labeled insulin present in the medium.
If the log of the velocity of total insulin degradation is plotted against the log of total insulin bound with no correction for nonspecific binding (Fig. 4) , a linear relationship is found. This has been demonstrated in freshly isolated (31) and primary cultures (26) of hepatocytes from normal rats and suggests that degradation velocity is first order with respect to the total amount of insulin bound. In addition, this relationship suggests that all insulin binding sites, including those involved in nonspecific binding, may mediate insulin degradation (26) . Thus, whereas the relationship between insulin binding and degradation is maintained in cells from group I Dex animals, there is more insulin degraded for a given amount of insulin bound.
To determine the nature of the 1251 associated with cells, hepatocytes from all groups of animals were solubilized as described in Methods and chromatographed on a column of Sephadex G-50. Fig. 5 demonstrates that the percentage of bound radioactivity that elutes with the second peak and coelutes with intact insulin is the same in the cells from control, group I, and group II Dex animals (72±4.1, 74.3±4.9, and 71±7.4%, respectively). Thus, even though the degradation velocity in the cells from group I Dex animals is increased, the percentage of degradation products retained by the cell at a given time is not increased. This suggests a more rapid disposal of these products into the medium. In vitro effects of dexamethasone on insulin binding, action, and degradation in cultured hepatocytes. To assess the role of dexamethasone itself in the changes in insulin binding, action, and degradation that we observed in freshly isolated hepatocytes from dexamethasone-treated rats, we exposed primary cultures of hepatocytes from normal rats to a high concentration of dexamethasone, 0.1 MM for 24 h. Under these conditions hepatocytes treated with dexamethasone bind significantly more insulin than control cells at high concentrations of insulin (10 nM, P < 0.05; 0.1 MM, P < 0.001) (Fig. 6) Because cells treated with dexamethasone are resistant to at least 1 parameter of insulin action, AIB uptake, we next evaluated whether these cells might be resistant to another action of insulin: the ability of insulin to down regulate its receptor. Fig. 7 illustrates that dexamethasone-treated cells are resistant to the ability of insulin to regulate its receptor. In these three experiments control cells incubated in the presence of insulin demonstrated a 52±3% decrease in insulin binding. These data are consistent with previous data from our laboratory, which demonstrated a 46-61% decrease in specific insulin binding to primary cultures of hepatocytes incubated with insulin and several agents that mimic insulin action (6).
DISCUSSION
Our studies were undertaken because previous work from our laboratory indicated that down regulation of the insulin receptor might be one of the many biological responses of a cell to insulin (6) (38) . Also, the addition of dexamethasone to primary cultures of rat hepatocytes had little effect on insulin binding but led to insulin resistance and an inability of insulin to down regulate its receptor.
Olefsky et al. (35) studied insulin binding in hepatocytes and adipocytes from rats receiving dexamethasone for 6 d and 3 wk at a dosage four times lower than the one used in this study. These authors observed partial recovery of insulin binding in hepatocytes and almost complete recovery in adipocytes after 3 wk of treatment and postulated that the return of insulin binding was related to an improvement in insulin resistance. This explanation is not supported by our data.
In fact, under the conditions of our studies, insulin resistance in hepatocytes worsens with prolonged dexamethasone treatment.
With regard to insulin degradation, because we (26) and others (31) have demonstrated a close correlation between insulin binding and degradation in hepatocytes from normal rats, it might be expected that hepatocytes from animals treated with dexamethasone for 1 wk would degrade less insulin. These hepatocytes, however, degrade more insulin. This suggests that degradation too can be regulated by postbinding mechanisms. Indeed hepatic insulin-degrading activity is decreased in liver homogenates (39) (40) (41) (42) and liver slices (42) from starved (39) and diabetic (40) (41) (42) animals. Similar findings have been reported for hepatic levels of glutathione-insulin transhydrogenase (43) . Freshly isolated hepatocytes from these animals also degrade less yet bind the same or increased quantities of insulin (5) . Thus, it appears that although insulin binding and degradation may be linked, it is likely that the response of the effector-degradative system(s) after binding is also regulated, perhaps independently of the receptor complex. Such regulation would explain why the normal relationship between insulin binding and degradation persists in hepatocytes from group I Dex animals but at an increased rate of degradation. It has been suggested (42) that the liver has an autoregulatory mechanism for the control of insulin degradation, which is governed at least partially by the level of insulin in the plasma. Although the mechanism by which the hyperinsulinemia present in group I Dex animals may lead to a faster rate of insulin degradation is unknown, one possible mechanism is by stimulation of the quantity or activity of degradative enzymes. With decreased binding, the quantity of insulin bound and internalized might be less, but the rate of degradation of internalized insulin might be greater. This situation would not alter the relationship between insulin binding and degradation but would result in more degradation for any amount of hormone bound (Figs.  4, 5 ). An alternative explanation is that the activity or quantity of degradative enzymes is unaltered but the rate of internalization of insulin is enhanced disproportionately to the decrease in receptor number. Because insulin degradation returned to normal when the hepatocytes became resistant to insulin with regard to AIB uptake (group II Dex) it is likely that this regulatory mechanism also requires that the cell be responsive to insulin.
The interpretation of in vivo studies is complicated by the many changes that occur in the hormonal and substrate milieu. To avoid these complicating factors and to further assess the role of dexamethasone itself in the changes in insulin binding, action, and degradation in dexamethasone-treated animals, we exposed primary cultures of rat hepatocytes from normal rats to dexamethasone, 0.1 MM, for 24 h. Under these conditions insulin binding at high concentrations of insulin was increased by dexamethasone treatment (Fig. 6 ). These findings suggest that the decrease in insulin binding observed in hepatocytes from rats treated with dexamethasone for 1 wk is due to the induced hyperinsulinemia and not the dexamethasone itself. Indeed, it is possible that the maintenance of insulin receptor number may be one of the many anabolic functions of glucocorticoids in the liver. Dexamethasone did not affect the basal rate of amino acid uptake in cultured hepatocytes. This is consistent with previous studies by Kletzien et al. (38) who demonstrated in the same cell system that dexamethasone has a synergestic effect with glucagon but by itself does not affect AIB uptake. In our studies dexamethasone did, however, render the primary cultures of hepatocytes resistant to insulin with regard to AIB uptake (Fig. 6 ). These cells, therefore, provided the opportunity to evaluate in vitro whether insulin can down regulate its receptor in an insulin-resistant cell. While parallel cultures incubated with insulin, 0.1 AM, in the absence of dexamethasone had a 52% decrease in insulin binding, cells incubated with dexamethasone, 0.1 MM, plus insulin, 0.1 M, were resistant to the ability of insulin to down regulate its receptor (Fig. 7) . These data support the conclusion that the return to control levels of insulin binding in hepatocytes from animals treated with dexamethasone for 4 wk is most likely due to the induction by dexamethasone of resistance to the ability of insulin to down regulate its receptor.
These studies emphasize the importance of post receptor events in the modulation of insulin binding, action, and degradation in the liver and support the hypothesis that down regulation of the hepatocyte insulin receptor is one of the many biological actions of insulin. It is important to note, however, that in a given metabolic state one or more tissues may be resistant (5, 44) to insulin but others may be responsive (5, 45 
